FDA Brief

Warning letters Food

FDA warning letter to

Beeyoutiful.com, LLC

LowIssued Jul 12, 2021Posted Jul 20, 2021Office of Human and Animal Food Operations-East

FDA warned Beeyoutiful.com that website claims made 26 supplement products unapproved drugs.

What happened

FDA reviewed www.beeyoutiful.com in April and May 2021 and found product pages and linked articles claiming that supplements such as Vitex w/ Dong Quai, Berry Well, and Colostrum Transfer Factor treat or prevent diseases including flu, cancer, urinary tract infections, and other conditions. FDA said these claims make the products drugs, and because they are not generally recognized as safe and effective for those uses and lack FDA approval, they are "new drugs." FDA also said some products are misbranded—illegal because their labeling lacks adequate directions for use—for diseases that require a licensed practitioner.

What FDA found

  1. The website claims show the products are intended to cure, mitigate, treat, or prevent disease, so FDA considers them drugs.

    FD&C Act section 201(g)(1)(B), 21 U.S.C. 321(g)(1)(B)
  2. The products are not generally recognized as safe and effective for the claimed uses and lack FDA approval, so they are "new drugs."

    FD&C Act sections 201(p), 301(d), and 505(a), 21 U.S.C. 321(p), 331(d), 355(a)
  3. Some products are misbranded because they do not bear adequate directions for their intended use.

    FD&C Act section 502(f)(1), 21 U.S.C. 352(f)(1); 21 CFR 201.5
  4. The products are intended for diseases that cannot be safely self-diagnosed or treated without a licensed practitioner, so adequate directions cannot be written for a layperson.

    FD&C Act section 502(f)(1), 21 U.S.C. 352(f)(1)
  5. Introducing these misbranded drugs into interstate commerce violates the Act.

    FD&C Act section 301(a), 21 U.S.C. 331(a)

What FDA wants

FDA tells the company it is responsible for investigating and determining the causes of the violations and for preventing their recurrence or other violations. The provided excerpt does not state a response deadline.

Who should pay attention

  • dietary supplement brands that make disease-treatment claims
  • online retailers and affiliate marketers of supplements
  • companies whose product pages link to health articles and testimonials

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk